Citadel Advisors
ONCR

Citadel Advisors’s Oncorus, Inc. ONCR Stock Holding History

Citadel Advisors’s Portfolio ONCR Stock Details ONCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,999
Closed -$8.95K – 15773
2023
Q1 		$8.95K Sell
25,999
-1,898,423
-99% -$708K ﹤0.01% 13616
2022
Q4 		$487K Buy
1,924,422
+9,828
+0.5% +$5.59K ﹤0.01% 8298
2022
Q3 		$1.63M Buy
1,914,594
+23,002
+1% +$29.5K ﹤0.01% 5991
2022
Q2 		$2.38M Buy
1,891,592
+3,123
+0.2% +$4.24K ﹤0.01% 5205
2022
Q1 		$3.36M Sell
1,888,469
-2,140
-0.1% -$6K ﹤0.01% 4949
2021
Q4 		$9.96M Buy
1,890,609
+8,099
+0.4% +$62.7K 0.01% 3084
2021
Q3 		$17.6M Sell
1,882,510
-18,460
-1% -$211K 0.02% 2197
2021
Q2 		$26.2M Buy
1,900,970
+7,935
+0.4% +$123K 0.03% 1761
2021
Q1 		$26.4M Buy
1,893,035
+13,698
+0.7% +$284K 0.03% 1645
2020
Q4 		$60.8M Buy
+1,879,337
New +$43.5M 0.07% 821

Other funds holding ONCR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return
YAL
Your Advocates Ltd Houston, Texas $328M AUM 19.81% 1-Year Est. Return